Bausch Health Cos EBITDA Margin 2012-2025 | BHC
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Bausch Health Cos (BHC) over the last 10 years. The current EBITDA margin for Bausch Health Cos as of December 31, 2025 is .
| Bausch Health Cos EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-12-31 | $10.27B | $3.12B | 30.34% |
| 2025-09-30 | $10.03B | $3.29B | 32.80% |
| 2025-06-30 | $9.86B | $3.00B | 30.45% |
| 2025-03-31 | $9.73B | $2.93B | 30.12% |
| 2024-12-31 | $9.63B | $2.95B | 30.65% |
| 2024-09-30 | $9.47B | $2.72B | 28.68% |
| 2024-06-30 | $9.20B | $2.41B | 26.16% |
| 2024-03-31 | $8.97B | $2.43B | 27.05% |
| 2023-12-31 | $8.76B | $2.32B | 26.44% |
| 2023-09-30 | $8.54B | $1.72B | 20.09% |
| 2023-06-30 | $8.35B | $1.97B | 23.64% |
| 2023-03-31 | $8.15B | $1.79B | 22.00% |
| 2022-12-31 | $8.12B | $1.95B | 23.97% |
| 2022-09-30 | $8.13B | $2.56B | 31.51% |
| 2022-06-30 | $8.19B | $2.93B | 35.80% |
| 2022-03-31 | $8.33B | $2.52B | 30.28% |
| 2021-12-31 | $8.43B | $2.06B | 24.39% |
| 2021-09-30 | $8.45B | $1.75B | 20.74% |
| 2021-06-30 | $8.48B | $1.69B | 19.92% |
| 2021-03-31 | $8.04B | $2.01B | 25.03% |
| 2020-12-31 | $8.03B | $2.56B | 31.92% |
| 2020-09-30 | $8.04B | $1.55B | 19.32% |
| 2020-06-30 | $8.11B | $1.51B | 18.62% |
| 2020-03-31 | $8.60B | $1.84B | 21.44% |
| 2019-12-31 | $8.60B | $1.94B | 22.50% |
| 2019-09-30 | $8.50B | $3.09B | 36.40% |
| 2019-06-30 | $8.43B | $3.07B | 36.38% |
| 2019-03-31 | $8.40B | $2.82B | 33.59% |
| 2018-12-31 | $8.38B | $0.51B | 6.13% |
| 2018-09-30 | $8.42B | $0.47B | 5.63% |
| 2018-06-30 | $8.51B | $0.41B | 4.77% |
| 2018-03-31 | $8.61B | $0.71B | 8.26% |
| 2017-12-31 | $8.72B | $3.11B | 35.66% |
| 2017-09-30 | $8.96B | $3.45B | 38.48% |
| 2017-06-30 | $9.22B | $2.56B | 27.71% |
| 2017-03-31 | $9.41B | $2.53B | 26.86% |
| 2016-12-31 | $9.67B | $2.42B | 24.99% |
| 2016-09-30 | $10.03B | $2.42B | 24.12% |
| 2016-06-30 | $10.34B | $3.74B | 36.15% |
| 2016-03-31 | $10.65B | $3.97B | 37.27% |
| 2015-12-31 | $10.45B | $4.14B | 39.63% |
| 2015-09-30 | $9.91B | $4.24B | 42.74% |
| 2015-06-30 | $9.18B | $4.20B | 45.74% |
| 2015-03-31 | $8.49B | $3.90B | 45.98% |
| 2014-12-31 | $8.21B | $3.69B | 44.91% |
| 2014-09-30 | $8.05B | $3.36B | 41.69% |
| 2014-06-30 | $7.53B | $2.28B | 30.25% |
| 2014-03-31 | $6.59B | $2.00B | 30.33% |
| 2013-12-31 | $5.77B | $1.70B | 29.39% |
| 2013-09-30 | $4.63B | $1.28B | 27.67% |
| 2013-06-30 | $3.97B | $1.47B | 37.10% |
| 2013-03-31 | $3.69B | $1.29B | 34.86% |
| 2012-12-31 | $3.48B | $1.10B | 31.67% |
| 2012-09-30 | $3.21B | $1.08B | 33.50% |
| 2012-06-30 | $2.93B | $1.08B | 36.94% |
| 2012-03-31 | $2.72B | $1.02B | 37.60% |
| 2011-12-31 | $2.43B | $0.94B | 38.73% |
| 2011-09-30 | $2.29B | $0.83B | 36.24% |
| 2011-06-30 | $1.90B | $0.47B | 24.83% |
| 2011-03-31 | $1.53B | $0.31B | 20.37% |
| 2010-12-31 | $1.18B | $0.17B | 14.04% |
| 2010-09-30 | $0.91B | $0.17B | 18.61% |
| 2010-06-30 | $0.91B | $0.35B | 38.23% |
| 2010-03-31 | $0.87B | $0.30B | 34.56% |
| 2009-12-31 | $0.82B | $0.32B | 38.86% |
| 2009-09-30 | $0.76B | $0.17B | 22.47% |
| 2009-06-30 | $0.73B | $0.15B | 20.99% |
| 2009-03-31 | $0.72B | $0.19B | 26.63% |
| 2008-12-31 | $0.76B | $0.21B | 27.12% |
| 2008-09-30 | $0.78B | $0.35B | 44.29% |
| 2008-06-30 | $0.79B | $0.32B | 41.17% |
| 2008-03-31 | $0.80B | $0.31B | 38.31% |
| 2007-12-31 | $0.84B | $0.34B | 40.57% |
| 2007-09-30 | $0.95B | $0.48B | 50.16% |
| 2007-06-30 | $1.05B | $0.53B | 50.29% |
| 2007-03-31 | $1.10B | $0.58B | 53.19% |
| 2006-12-31 | $1.07B | $0.57B | 52.80% |
| 2006-09-30 | $1.05B | $0.54B | 50.95% |
| 2006-06-30 | $1.02B | $0.58B | 56.47% |
| 2006-03-31 | $0.98B | $0.52B | 52.85% |
| 2005-12-31 | $0.94B | $0.46B | 49.25% |
| 2005-09-30 | $0.93B | $0.39B | 42.03% |
| 2005-06-30 | $0.89B | $0.32B | 36.34% |
| 2005-03-31 | $0.88B | $0.34B | 39.09% |
| 2004-12-31 | $0.89B | $0.36B | 40.70% |
| 2004-09-30 | $0.81B | $0.30B | 37.08% |
| 2004-06-30 | $0.81B | $0.30B | 36.88% |
| 2004-03-31 | $0.82B | $0.35B | 42.61% |
| 2003-12-31 | $0.82B | $0.38B | 46.17% |
| 2003-09-30 | $0.86B | $0.46B | 53.25% |
| 2003-06-30 | $0.86B | $0.49B | 56.66% |
| 2003-03-31 | $0.82B | $0.45B | 54.13% |
| 2002-12-31 | $0.79B | $0.42B | 53.68% |
| 2002-09-30 | $0.73B | $0.39B | 53.92% |
| 2002-06-30 | $0.67B | $0.37B | 55.07% |
| 2002-03-31 | $0.62B | $0.33B | 53.47% |
| 2001-12-31 | $0.58B | $0.32B | 54.89% |
| 2001-09-30 | $0.51B | $0.25B | 49.11% |
| 2001-06-30 | $0.44B | $0.20B | 46.15% |
| 2001-03-31 | $0.37B | $0.17B | 47.01% |
| 2000-12-31 | $0.30B | $0.13B | 44.26% |
| 2000-09-30 | $0.26B | $0.12B | 47.33% |
| 2000-06-30 | $0.22B | $0.10B | 47.49% |
| 2000-03-31 | $0.20B | $0.10B | 48.72% |
| 1999-12-31 | $0.18B | $0.09B | 50.00% |
| 1999-09-30 | $0.15B | $0.07B | 48.30% |
| 1999-06-30 | $0.13B | $0.06B | 48.46% |
| 1999-03-31 | $0.12B | $0.06B | 47.90% |
| 1998-12-31 | $0.11B | $0.05B | 47.79% |
| 1998-09-30 | $0.10B | $0.06B | 60.78% |
| 1998-06-30 | $0.09B | $0.07B | 72.34% |
| 1998-03-31 | $0.09B | $0.07B | 74.71% |
| 1997-12-31 | $0.08B | $0.06B | 76.54% |
| 1997-09-30 | $0.07B | $0.05B | 71.01% |
| 1997-06-30 | $0.07B | $0.04B | 53.03% |
| 1997-03-31 | $0.07B | $0.03B | 50.00% |
| 1996-12-31 | $0.07B | $0.04B | 61.19% |
| 1996-09-30 | $0.06B | $0.04B | 59.68% |
| 1996-06-30 | $0.05B | $0.03B | 70.21% |
| 1996-03-31 | $0.03B | $0.03B | 93.75% |
| 1995-12-31 | $0.02B | $0.02B | 100.00% |
| 1995-09-30 | $0.02B | $0.02B | 100.00% |
| 1995-06-30 | $0.02B | $0.02B | 100.00% |
| 1995-03-31 | $0.02B | $0.02B | 80.95% |
| 1994-12-31 | $0.02B | $0.01B | 76.47% |
| 1994-06-30 | $0.01B | $0.00B | 33.33% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.222B | $9.625B |
| Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $39.071B | 12.09 |
| BridgeBio Pharma (BBIO) | United States | $14.501B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.806B | 18.36 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.915B | 23.87 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.310B | 9.44 |
| Taysha Gene Therapies (TSHA) | United States | $1.246B | 0.00 |
| Personalis (PSNL) | United States | $0.729B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.422B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.187B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.055B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |